The FDA has extended its review timeline for relutrigine, an experimental treatment for SCN2A- and SCN8A-related developmental and epileptic encephalopathy (DEE), shifting the target action date from September 27, 2026, to December 27, 2026. The agency classified additional sensitivity analyses of clinical data submitted by Praxis Precision Medicines as a major amendment, which triggered the three-month extension.
The delay was announced in late June, well before the original Prescription Drug User Fee Act (PDUFA) date. According to the company, the FDA did not raise safety or manufacturing concerns. Praxis clarified that the extension resulted solely from the new data analyses rather than a request for additional clinical studies.
Relutrigine represents the first therapy designed to selectively reduce neuronal hyperexcitability linked to seizures in these rare genetic disorders. The drug holds breakthrough therapy designation from both the FDA and the European Medicines Agency, along with orphan drug and rare pediatric disease designations covering SCN2A-DEE, SCN8A-DEE, and Dravet syndrome. If approved, Praxis could qualify for a priority review voucher.
The drug’s development accelerated in early 2026 when the FDA accepted its New Drug Application (NDA) and granted priority review. A mid-cycle review conducted in August 2026 identified no major safety or efficacy concerns. The agency has not scheduled an advisory committee meeting before the December decision.
Praxis has already begun preparing for potential approval, hiring commercial and medical leadership, building inventory, and engaging with payers. The company also reported that no serious adverse events linked to relutrigine were observed in clinical trials.
Read Also: FDA approves first treatments for rare ataxia disorders
The NDA submission relies primarily on the EMBOLD study, a registrational trial involving 51 patients with SCN2A- and SCN8A-DEE. Over a 16-week period, relutrigine reduced motor seizure frequency by 53% compared to placebo, while increasing seizure-free days by 66%. Clinicians and caregivers noted statistically significant improvements in behavior, alertness, and communication.
An independent data monitoring committee recommended terminating the trial early after meeting predefined efficacy thresholds. Earlier results from a smaller EMBOLD cohort of 16 patients showed a 46% reduction in seizures, with over 30% achieving seizure freedom during a 28-day assessment. In an open-label extension phase, patients experienced a median 75% reduction in seizure rates, with five individuals becoming seizure-free.
Beyond SCN2A- and SCN8A-DEE, Praxis is evaluating relutrigine in the EMERALD trial, which includes over 50 genetic causes of DEE and has enrolled approximately 200 patients. Topline results from this study are expected in the fourth quarter of 2026. If positive, they could support a supplemental NDA submission in 2027.
Relutrigine’s mechanism of action targets persistent sodium currents in neurons, aiming to dampen disease-driven hyperexcitability without broadly affecting normal sodium channel activity. This distinguishes it from existing antiseizure medications, which typically suppress neuronal activity more broadly.
